American Academy of Otolaryngic Allergy Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial
2014
NCT02493257
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

American Academy of Otolaryngic Allergy & Foundation

Active Ingredients

Drugs in Phase 3 Trials (2)

capsaicin (qutenza) (2 trials)

lidocaine (xylocaine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Rhinitis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2